Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac192
Abstract: OBJECTIVE Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors. Our previous study reported LILRA3 transcripts were markedly upregulated in neutrophils from patients with antiphospholipid syndrome (APS). We undertook this study to… read more here.
Keywords: lilra3; mpo dna; dna complexes; antiphospholipid syndrome ... See more keywords
Comparison of the Serum Metabolic Signatures Based on 1 H NMR between Thrombotic Antiphospholipid Syndrome (APS) Patients and Healthy Individuals
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131927
Abstract: Antiphospholipid syndrome (APS) is an acquired immuno-mediated disorder, in which antiphospholipid antibodies (aPL) against a variety of phospholipids and phospholipid transport proteins are persistently produced. aPL include a heterogeneous group of circulating immunoglobulins: lupus anticoagulant… read more here.
Keywords: antiphospholipid syndrome; healthy individuals; comparison serum; syndrome aps ... See more keywords